公开(公告)号：US12186375B2

公开(公告)日：2025-01-07

申请号：US17112280

申请日：2020-12-04

Applicant: Bioverativ Therapeutics Inc.

Inventor： Jennifer A. Dumont ,  Susan Low ,  Alan J. Bitonti ,  Glenn Pierce ,  Alvin Luk ,  Haiyan Jiang ,  Byron McKinney ,  Matt Ottmer ,  Jurg Sommer ,  Karen Nugent ,  Lian Li ,  Robert T. Peters

IPC: A61K38/37 ,  A61K47/60 ,  A61K47/68 ,  C07K14/755 ,  G01N33/86

Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US12161696B2

公开(公告)日：2024-12-10

申请号：US16463748

申请日：2017-12-01

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer Dumont ,  Nisha Jain ,  Desilu Glazebrook

IPC: A61K38/37 ,  A61K38/48 ,  A61P7/04 ,  A61P19/02

Abstract: The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.

公开(公告)号：US20240350671A1

公开(公告)日：2024-10-24

申请号：US18440712

申请日：2024-02-13

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Ajay Maghodia ,  Philip Zakas

IPC: A61K48/00 ,  C07K14/755 ,  C12N15/86

CPC classification number: A61K48/0058 ,  C07K14/755 ,  C12N15/86 ,  C12N2710/14043 ,  C12N2830/008 ,  C12N2830/42

Abstract: The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). Also disclosed are methods of using the nucleic acid molecules in gene therapy applications.

公开(公告)号：US20240294940A1

公开(公告)日：2024-09-05

申请号：US18440711

申请日：2024-02-13

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Tongyao Liu ,  Ajay Maghodia ,  Philip Zakas

IPC: C12N15/86 ,  C07K14/005

CPC classification number: C12N15/86 ,  C07K14/005 ,  C12N2710/14043 ,  C12N2710/14044 ,  C12N2710/14052 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14222 ,  C12N2750/14243 ,  C12N2750/14322 ,  C12N2750/14343 ,  C12N2800/30

Abstract: Provided herein is a baculovirus expression vector system for the production of a desired protein. In one aspect, the desired protein is a closed-ended DNA (ceDNA) molecule comprising wild-type and/or truncated inverted terminal repeats derived from a genome of a member of the viral family Parvoviridae.

公开(公告)号：US20240287158A1

公开(公告)日：2024-08-29

申请号：US18572006

申请日：2022-06-23

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Tyler CARLAGE ,  Randall MAULDIN ,  Loubna Mzaalak TAZI ,  Timothy R. MCCOY

IPC: C07K14/755 ,  A61K38/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26

CPC classification number: C07K14/755 ,  A61K47/02 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K38/00 ,  C07K2319/30

Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

公开(公告)号：US20240212861A1

公开(公告)日：2024-06-27

申请号：US18499693

申请日：2023-11-01

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Haiyan JIANG

IPC: G16H50/50 ,  A61K38/37 ,  A61K38/48 ,  C07K14/755 ,  C12N9/64 ,  G06N7/01 ,  G16C20/30 ,  G16C20/70 ,  G16H20/10 ,  G16H40/67

CPC classification number: G16H50/50 ,  A61K38/37 ,  A61K38/4846 ,  C07K14/755 ,  C12N9/644 ,  C12Y304/21022 ,  G06N7/01 ,  G16C20/30 ,  G16C20/70 ,  G16H20/10 ,  G16H40/67 ,  G16C20/90

Abstract: The present invention is directed to computer based pharmacokinetics systems, such as, web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy.

公开(公告)号：US20230331774A1

公开(公告)日：2023-10-19

申请号：US18153669

申请日：2023-01-12

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glen BOLTON ,  Keith SELVITELLI

IPC: C07K1/22 ,  A61L2/00 ,  C07K16/06 ,  C07K1/16 ,  C07K14/755

CPC classification number: C07K1/22 ,  A61L2/0088 ,  C07K16/065 ,  C07K1/165 ,  C07K14/755 ,  A61L2202/21 ,  C07K2319/30

Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.

公开(公告)号：US20230322901A1

公开(公告)日：2023-10-12

申请号：US18068288

申请日：2022-12-19

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： John KULMAN

IPC: C07K14/755 ,  C07K14/59 ,  C07K14/79 ,  A61K38/37 ,  A61K35/14 ,  C07K14/00 ,  C07K14/435 ,  C07K14/705 ,  C07K14/76

CPC classification number: C07K14/755 ,  C07K14/59 ,  C07K14/79 ,  A61K38/37 ,  A61K35/14 ,  C07K14/00 ,  C07K14/43504 ,  C07K14/705 ,  C07K14/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/60 ,  A61K38/00

Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

公开(公告)号：US11747351B2

公开(公告)日：2023-09-05

申请号：US16848445

申请日：2020-04-14

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jurg Sommer ,  Haiyan Jiang ,  Xin Zhang ,  Buyue Yang ,  Glenn Pierce

IPC: G01N33/86 ,  C12N9/64

CPC classification number: G01N33/86 ,  C12N9/644 ,  G01N2333/755 ,  G01N2333/9645 ,  G01N2333/974

Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

公开(公告)号：US20230023927A1

公开(公告)日：2023-01-26

申请号：US17830745

申请日：2022-06-02

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Robert T. PETERS ,  Adam R. MEZO ,  Daniel S. RIVERA ,  Alan J. BITONTI ,  Susan C. LOW

IPC: C07K14/755 ,  C07K14/555 ,  A61K47/64 ,  A61K47/68 ,  C07K14/59 ,  C07K14/475 ,  C07K16/00 ,  C12N9/64 ,  C07K14/565 ,  A61K47/60 ,  C07K14/505 ,  C07K14/705 ,  C07K14/745 ,  C12N9/96 ,  C07K14/61 ,  C07K14/56 ,  A61K38/00

Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.